NCT01521546View on ClinicalTrials.gov

Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

eplerenone

25mg tablet, once daily by mouth for 12 months

DRUG

placebo

one tablet by mouth daily for 12 months

Trial Locations (3)

43210

The Ohio State University Medical Center, Columbus

90095-1743

Mattel Children's Hospital and David Geffen School of Medicine at UCLA, Los Angeles

Unknown

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
collaborator

Ballou Skies

OTHER

lead

Subha Raman

OTHER

NCT01521546 - Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter